{"schema_version":"1.0","type":"article","title":"中樞神經新藥要靠「神經發炎」？","url":"https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.md","lang":"zh-Hant","date":"2026-05-13","publish_at":"2026-05-13T10:30:00+08:00","updated_at":"2026-05-13","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","Alzheimer","CNS","Pfizer"],"summary":"【屢敗屢戰的中樞神經新藥，能否靠「神經發炎」打贏翻身仗？】中樞神經系統新藥研發，一直是創新藥裡最難啃的一塊骨頭。🧠 不是市場不大。恰恰相反，阿茲海默症、帕金森氏症、肌萎縮性脊髓側索硬化症、多發性硬化症","key_points":[],"facts":[],"sections":["01｜中樞神經新藥為什麼這麼難？","02｜資本退潮後，為什麼「神經發炎」反而成了例外？","03｜神經發炎不是副產物，而可能是疾病推進器","04｜BHV-8000：把自體免疫藥物邏輯帶進帕金森氏症","05｜TREM2：小膠質細胞從清道夫變成治療標靶","06｜LRRK2：帕金森氏症裡的蛋白清除與免疫交界點","07｜NLRP3、NEK7、C1q、S1P：神經發炎不是單一路線，而是一組免疫網路","08｜破局關鍵：中樞神經要抄免疫藥的作業，但不能照抄","09｜台灣的CNS新藥有誰？"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"media.crai.com","source":"","date":"","url":""},{"title":"https://media.crai.com/wp-content/uploads/2024/09/13110655/Approaching-the-final-frontier-golden-decade-of-drug-development-for-the-central-nervous-system-Sept2024.pdf","source":"","date":"","url":"https://media.crai.com/wp-content/uploads/2024/09/13110655/Approaching-the-final-frontier-golden-decade-of-drug-development-for-the-central-nervous-system-Sept2024.pdf"},{"title":"media.crai.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"www.biospace.com","source":"","date":"","url":""},{"title":"https://www.biospace.com/amgen-closes-out-its-neuroscience-programs-as-it-focuses-on-long-term-growth-areas","source":"","date":"","url":"https://www.biospace.com/amgen-closes-out-its-neuroscience-programs-as-it-focuses-on-long-term-growth-areas"},{"title":"www.biospace.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"www.biohaven.com","source":"","date":"","url":""},{"title":"https://www.biohaven.com/wp-content/uploads/BIOHAVEN-AAN-BHV-8000-2025_FINAL-Read-Only.pdf","source":"","date":"","url":"https://www.biohaven.com/wp-content/uploads/BIOHAVEN-AAN-BHV-8000-2025_FINAL-Read-Only.pdf"},{"title":"www.biohaven.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/markets/deals/sanofi-acquire-vigil-neuroscience-470-million-deal-2025-05-21/","source":"","date":"","url":"https://www.reuters.com/markets/deals/sanofi-acquire-vigil-neuroscience-470-million-deal-2025-05-21/"},{"title":"www.reuters.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：中樞神經新藥要靠「神經發炎」？","url":"https://drugnews.com.tw/assets/articles/neuroinflammation-cns-drug-comeback/dcard-01.webp"},{"alt":"Dcard 原圖：中樞神經新藥要靠「神經發炎」？","url":"https://drugnews.com.tw/assets/articles/neuroinflammation-cns-drug-comeback/dcard-02.png"},{"alt":"Dcard 原圖：中樞神經新藥要靠「神經發炎」？","url":"https://drugnews.com.tw/assets/articles/neuroinflammation-cns-drug-comeback/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/neuroinflammation-cns-drug-comeback/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-13）。中樞神經新藥要靠「神經發炎」？。https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-13-neuroinflammation-cns-drug-comeback-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}